Opana developed by Endo is used for the relief of moderate to severe acute pain where the use of an opioid is appropriate.

ER Opana

Opana ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid therapy for a longer period of time.  Opana ER is not intended for use as a prn analgesic and also it is not indicated for pain in the immediate postoperative period (12?24 hours following surgery) for patients not previously taking opioids because of the risk of oversedation and respiratory depression requiring reversal with opioid antagonists.  Opana ER is not indicated for pain in the postoperative period if the pain is mild or not expected to continue for an extended period of time.

Opana Oxymorphone 

Oxymorphone (Opana) or 14-Hydroxydihydromorphinone is a powerful semi-synthetic opioid analgesic that is derived from thebaine, and is approximately 6-8 times more potent than morphine. Clinically, it is administered as its hydrochloride salt via injection, or suppository; normally in dosages of 1 mg (injected) to 5 mg (suppository). Endo Pharmaceuticals markets oxymorphone in the US as Opana and Opana ER. Opana is available as 5 mg and 10 mg tablets and Opana ER, an extended-release form of oxymorphone, is available as tablets in strengths of 5 mg, 10 mg, 20 mg, and 40 mg. As with other opioids, oxymorphone may cause physical dependency, and may be abused.

ER Opana Oxymorphone

ER Opana Oxymorphone is indicated for the relief of moderate to severe pain and also as a preoperative medication to alleviate apprehension, maintain anesthesia, and as an obstetric analgesic. In addition, it can be used for the alleviation of patients with dyspnea associated with acute left ventricular failure and pulmonary edema.